Merits & Tree adds five partners for three offices in China

Merits & tree adds five partners
From the top left: Fu Huahua, Li Zeyu
From the bottom left: Wang Haiqing, Qu Henxi and Lv Jingya

Merits & Tree Law Offices hires five partners for three locations with Wang Haiqing and Qu Chenxi joining the Beijing office, Fu Huahua and Li Zeyu in Shanghai and Lv Jingya in the Wuhan office.

Wang had been a senior partner at Anli Partners before joining Merits & Tree and Qu also worked at the same firm. Both are experienced in dispute resolution, and banking and financing. Before joining Anli, Wang was a partner at Duan & Duan Law Firm and Chang-An Law Firm.

Wang has presided over many significant commercial disputes, including the credit assignment contract between China Huarong Asset Management Company and Jinbei Automotive, with the loss of state-owned assets of nearly RMB100 million, and the equity dispute case involving Beijing restaurant chain Yuxiang Kitchen.

Qu, who also focuses on government regulation and compliance, covers practice areas including real estate construction, mineral and energy, finance, and company-related disputes.

Wuhan-based Lv had been a partner at Yuanshen Law Firm, while Fu, who will join the Shanghai office, worked at Grandway Law Offices. Both partners focus on special assets, restructuring and insolvency, real estate and infrastructure and dispute resolution.

Fu’s expertise covers litigation and arbitration in banking and finance, real estate, infrastructure, and culture and media industries, as well as cross-border mergers and acquisitions.

Lv’s specialties are in land development and construction. She has established restructuring plans for several state-owned enterprises in Hubei, and she is able to provide legal services for share incentives and financing for reorganised enterprises through financial instruments such as REITs and service trusts.

Formerly a partner at Zhong Lun Law Firm, Li’s expertise covers investment and M&A financing, private equity and investment funds.

In 2022, Li was one of the leading partners in a nearly USD100 million investment in ImmuneOnco Biopharmaceuticals, an anti-tumor immunotherapy product development company. She also advised BeiGene on a USD772 million cross-border intellectual property licensing deal.